Radiofrequency Ablation of Chondroblastoma: Long-term Clinical and Imaging Outcomes
Overview
Authors
Affiliations
Objectives: To investigate the long-term clinical and imaging outcomes of patients with chondroblastoma treated by radiofrequency ablation (RFA).
Methods: Retrospective analysis of 25 consecutive patients treated with RFA from September 2006 to December 2013. Patients were reviewed within one month of the procedure, then every 3-6 months, and yearly for up to three years. Serial magnetic resonance imaging (MRI) was performed at follow-up to monitor recovery. Functional outcome was assessed using the Musculoskeletal Tumour Society Score (MSTS).
Results: Pre-procedure MRI confirmed osteolytic lesions (size range 1.0-3.3 cm; mean 2.0 cm). Patients reported continued symptomatic improvement at four months review. Serial MRI confirmed progressive resolution of inflammation with fatty consolidation of cavity. 88 % of patients became asymptomatic during the follow up period. Three patients' (12 %) symptoms returned at 16, 22 and 24 months respectively after RFA. MRI and biopsy confirmed recurrence in these patients. Functional assessment using MSTS score had an average score of 97.5 %. Mean follow up for the study group was 49 months.
Conclusion: RFA is an effective alternative to surgery in the management of chondroblastoma. We recommend a multi-disciplinary approach and RFA should be considered as a first-line treatment. Long-term follow-up is required for timely detection of recurrences.
Key Points: • RFA is a safe and effective technique in the treatment of chondroblastoma. • Positive outcomes in 88 % patients at mean follow-up period of 49 months. • Local recurrences occurred in 12 % cases. • Long-term follow-up is required for timely detection of recurrences. • RFA should be considered as a first-line treatment for chondroblastoma.
Hirozane T, Sekita T, Kobayashi E, Mori T, Asano N, Udaka T BMC Surg. 2025; 25(1):40.
PMID: 39856613 PMC: 11761176. DOI: 10.1186/s12893-025-02782-3.
Chondroblastoma of the femoral head: curettage without dislocation.
Yang D, Ouyang H, Zhou Z, Wang Z BMC Surg. 2024; 24(1):363.
PMID: 39558306 PMC: 11572398. DOI: 10.1186/s12893-024-02660-4.
Minimally invasive interventional guided imaging therapies of musculoskeletal tumors.
Tomas X, Cornellas L, Bassaganyas C, Blasco-Andaluz J, Cayon-Somacarrera S, Martel-Villagran J Quant Imaging Med Surg. 2024; 14(11):7908-7936.
PMID: 39544466 PMC: 11558482. DOI: 10.21037/qims-24-452.
Muratori F, Scanferla R, Roselli G, Frenos F, Campanacci D BMC Musculoskelet Disord. 2023; 24(1):139.
PMID: 36814214 PMC: 9945643. DOI: 10.1186/s12891-023-06239-7.
Chen C, Li Z, Xue J, Shi Z Front Surg. 2023; 9:1039785.
PMID: 36684231 PMC: 9849586. DOI: 10.3389/fsurg.2022.1039785.